SCHEMBL3430813

SCHEMBL3430813

CCN(CC)S(=O)(=O)c1ccc(Cn2nc(C(=O)Nc3nc4ccccc4s3)c3ccccc32)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.51
KDM4E B2RXH2 6/20 0.50
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
ALDH1A1 P00352 4/20 0.49
HTT P42858 4/20 0.49
LMNA P02545 4/20 0.49
MAPK1 P28482 3/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
TP53 P04637 2/20 0.49
HPGD P15428 2/20 0.49
TSHR P16473 2/20 0.49
USP2 O75604 1/20 0.49
HSD17B10 Q99714 1/20 0.49
POLB P06746 1/20 0.47
AKR1B1 P15121 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NPC1 O15118 1/20 0.46
CNR1 P21554 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3433127 0.89 HTT (0.47) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL3431653 0.80 NPC1 (0.52) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4250971 0.78 CNR1 (0.46) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL3430598 0.76 LRRK2 (0.53) KDM4ERAB9ASMN1; SMN2TSHRAKR1B1
SCHEMBL3428566 0.76 SMN1; SMN2 (0.49) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL3431088 0.75 KDM4E (0.45) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6532344 0.74 ALDH1A1 (0.48) MAPTALDH1A1HTTLMNARAB9A
SCHEMBL3428278 0.72 NPC1 (0.55) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL3429672 0.72 ATR (0.50) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4250973 0.72 PHOSPHO1 (0.45) MAPTMEN1KMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP claimed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US claimed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO claimed
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 MAPT 3715/4885KDM4E 1965/4885MEN1 3958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.